Drug Pricing: Policy and Politics
Despite bipartisan agreement that the high cost of drugs must be addressed, proposals to reform the U.S. drug pricing system have languished for years. There’s no shortage of ideas on what to do—Medicare price negotiation, greater price transparency, international reference pricing, patent exclusivity changes, and price controls all have their advocates. But there’s no consensus on how to strike the right balance between making drugs affordable now, and preserving financial incentives for developing new drugs in the future. Join our expert panel as they discuss the policy options for drug pricing, the appropriate roles of government and markets, and prospects for reform in the current political environment.
Supported by the Charles C. Leighton, MD Memorial Lecture Fund.
Craig Garthwaite, PhD, MPP
Herman R. Smith Research Professor in Hospital and Health Services, Professor of Strategy, and Director, Program on Healthcare, Kellogg School of Management, Northwestern University
Rachel Sachs, JD, MPH
Professor of Law, Washington University School of Law
Mariana Socal, MD, PhD, MS, MPP
Associate Scientist, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health
Rachel M. Werner, MD, PhD (moderator)
Executive Director, Penn LDI; Robert D. Eilers Professor, Medicine and Health Care Management, Perelman School of Medicine and the Wharton School
TO JOIN, PLEASE SELECT FROM THE FOLLOWING OPTIONS: